First Time Loading...

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 7.44 USD 3.05%
Updated: Mar 28, 2024

ROE
Return on Equity

-42.5%
Current
-41%
Average
-29.6%
Industry
Negative for the last year
-42.5%
Negative average
-41%
Worse than average
Worse than industry value

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-42.5%
=
Net Income
-153.2m
/
Equity
360.6m

ROE Across Competitors

ROE Comparison
Editas Medicine Inc Competitors

Country US
Market Cap 607.8m USD
ROE
-42%
Country US
Market Cap 319.7B USD
ROE
35%
Country US
Market Cap 153.2B USD
ROE
136%
Country US
Market Cap 108.4B USD
ROE
23%
Country US
Market Cap 105.1B USD
ROE
16%
Country US
Market Cap 91.4B USD
ROE
26%
Country AU
Market Cap 139.1B AUD
ROE
15%
Country US
Market Cap 43.1B USD
ROE
-28%
Country US
Market Cap 41.6B USD
ROE
-29%
Country US
Market Cap 31.2B USD
ROE
8%
Country KR
Market Cap 40.1T KRW
ROE
14%

ROE Distribution

ROE Distribution
Biotechnology Industry

Profitability Report

View the profitability report to see the full profitability analysis for Editas Medicine Inc.

See Also

Discover More
What is Return on Equity?

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-42.5%
=
Net Income
-153.2m
/
Equity
360.6m
What is the ROE of Editas Medicine Inc?

Based on Editas Medicine Inc's most recent financial statements, the company has ROE of -42.5%.